vs
Side-by-side financial comparison of Boston Scientific (BSX) and Revvity (RVTY). Click either name above to swap in a different company.
Boston Scientific is the larger business by last-quarter revenue ($5.2B vs $772.1M, roughly 6.7× Revvity). Boston Scientific runs the higher net margin — 25.7% vs 12.7%, a 13.0% gap on every dollar of revenue. On growth, Boston Scientific posted the faster year-over-year revenue change (11.6% vs 5.9%). Over the past eight quarters, Boston Scientific's revenue compounded faster (12.4% CAGR vs 9.0%).
Boston Scientific Corporation (BSC) is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Revvity, Inc. is an American company in the life sciences and diagnostics business that is focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy or gene therapy developments. Its origins lie with the long-existing company PerkinElmer, which has been in a variety of business lines.
BSX vs RVTY — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $5.2B | $772.1M |
| Net Profit | $1.3B | $98.4M |
| Gross Margin | 69.5% | — |
| Operating Margin | — | 14.5% |
| Net Margin | 25.7% | 12.7% |
| Revenue YoY | 11.6% | 5.9% |
| Net Profit YoY | 99.0% | 3.9% |
| EPS (diluted) | $0.90 | $0.86 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $5.2B | — | ||
| Q4 25 | $5.3B | $772.1M | ||
| Q3 25 | $5.1B | $698.9M | ||
| Q2 25 | $5.1B | $720.3M | ||
| Q1 25 | $4.7B | $664.8M | ||
| Q4 24 | $4.6B | $729.4M | ||
| Q3 24 | $4.2B | $684.0M | ||
| Q2 24 | $4.1B | $691.7M |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $670.0M | $98.4M | ||
| Q3 25 | $755.0M | $46.7M | ||
| Q2 25 | $795.0M | $53.9M | ||
| Q1 25 | $672.0M | $42.2M | ||
| Q4 24 | $563.0M | $94.6M | ||
| Q3 24 | $468.0M | $94.4M | ||
| Q2 24 | $322.0M | $55.4M |
| Q1 26 | 69.5% | — | ||
| Q4 25 | 69.6% | — | ||
| Q3 25 | 69.9% | 53.6% | ||
| Q2 25 | 67.7% | 54.5% | ||
| Q1 25 | 68.8% | 56.5% | ||
| Q4 24 | 67.8% | — | ||
| Q3 24 | 68.8% | 56.3% | ||
| Q2 24 | 69.2% | 55.7% |
| Q1 26 | — | — | ||
| Q4 25 | 15.6% | 14.5% | ||
| Q3 25 | 20.7% | 11.7% | ||
| Q2 25 | 16.2% | 12.6% | ||
| Q1 25 | 19.8% | 10.9% | ||
| Q4 24 | 14.8% | 16.3% | ||
| Q3 24 | 17.4% | 14.3% | ||
| Q2 24 | 12.6% | 12.4% |
| Q1 26 | 25.7% | — | ||
| Q4 25 | 12.7% | 12.7% | ||
| Q3 25 | 14.9% | 6.7% | ||
| Q2 25 | 15.7% | 7.5% | ||
| Q1 25 | 14.4% | 6.4% | ||
| Q4 24 | 12.3% | 13.0% | ||
| Q3 24 | 11.1% | 13.8% | ||
| Q2 24 | 7.8% | 8.0% |
| Q1 26 | $0.90 | — | ||
| Q4 25 | $0.45 | $0.86 | ||
| Q3 25 | $0.51 | $0.40 | ||
| Q2 25 | $0.53 | $0.46 | ||
| Q1 25 | $0.45 | $0.35 | ||
| Q4 24 | $0.38 | $0.77 | ||
| Q3 24 | $0.32 | $0.77 | ||
| Q2 24 | $0.22 | $0.45 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $919.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $7.3B |
| Total Assets | — | $12.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $2.0B | $919.9M | ||
| Q3 25 | $1.3B | $931.4M | ||
| Q2 25 | $534.0M | $991.8M | ||
| Q1 25 | $725.0M | $1.1B | ||
| Q4 24 | $414.0M | $1.2B | ||
| Q3 24 | $2.5B | $1.2B | ||
| Q2 24 | $2.9B | $2.0B |
| Q1 26 | — | — | ||
| Q4 25 | $11.1B | — | ||
| Q3 25 | $11.1B | — | ||
| Q2 25 | $11.1B | — | ||
| Q1 25 | $10.5B | — | ||
| Q4 24 | $9.0B | — | ||
| Q3 24 | $9.2B | — | ||
| Q2 24 | $9.0B | — |
| Q1 26 | — | — | ||
| Q4 25 | $24.2B | $7.3B | ||
| Q3 25 | $23.4B | $7.4B | ||
| Q2 25 | $22.4B | $7.6B | ||
| Q1 25 | $22.2B | $7.6B | ||
| Q4 24 | $21.8B | $7.7B | ||
| Q3 24 | $20.7B | $7.9B | ||
| Q2 24 | $20.4B | $7.9B |
| Q1 26 | — | — | ||
| Q4 25 | $43.7B | $12.2B | ||
| Q3 25 | $42.7B | $12.1B | ||
| Q2 25 | $41.6B | $12.4B | ||
| Q1 25 | $40.1B | $12.4B | ||
| Q4 24 | $39.4B | $12.4B | ||
| Q3 24 | $38.1B | $12.8B | ||
| Q2 24 | $37.1B | $13.4B |
| Q1 26 | — | — | ||
| Q4 25 | 0.46× | — | ||
| Q3 25 | 0.48× | — | ||
| Q2 25 | 0.50× | — | ||
| Q1 25 | 0.47× | — | ||
| Q4 24 | 0.41× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.44× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $182.0M |
| Free Cash FlowOCF − Capex | — | $161.8M |
| FCF MarginFCF / Revenue | — | 21.0% |
| Capex IntensityCapex / Revenue | — | 2.6% |
| Cash ConversionOCF / Net Profit | — | 1.85× |
| TTM Free Cash FlowTrailing 4 quarters | — | $509.4M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $1.4B | $182.0M | ||
| Q3 25 | $1.3B | $138.5M | ||
| Q2 25 | $1.3B | $134.3M | ||
| Q1 25 | $541.0M | $128.2M | ||
| Q4 24 | $1.5B | $174.2M | ||
| Q3 24 | $1.0B | $147.9M | ||
| Q2 24 | $813.0M | $158.6M |
| Q1 26 | — | — | ||
| Q4 25 | $1.0B | $161.8M | ||
| Q3 25 | $1.2B | $120.0M | ||
| Q2 25 | $1.1B | $115.5M | ||
| Q1 25 | $354.0M | $112.2M | ||
| Q4 24 | $1.2B | $149.8M | ||
| Q3 24 | $823.0M | $125.6M | ||
| Q2 24 | $658.0M | $136.6M |
| Q1 26 | — | — | ||
| Q4 25 | 19.2% | 21.0% | ||
| Q3 25 | 22.9% | 17.2% | ||
| Q2 25 | 22.3% | 16.0% | ||
| Q1 25 | 7.6% | 16.9% | ||
| Q4 24 | 25.8% | 20.5% | ||
| Q3 24 | 19.6% | 18.4% | ||
| Q2 24 | 16.0% | 19.7% |
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | 2.6% | ||
| Q3 25 | 3.6% | 2.6% | ||
| Q2 25 | 3.1% | 2.6% | ||
| Q1 25 | 4.0% | 2.4% | ||
| Q4 24 | 6.1% | 3.4% | ||
| Q3 24 | 4.3% | 3.3% | ||
| Q2 24 | 3.8% | 3.2% |
| Q1 26 | — | — | ||
| Q4 25 | 2.04× | 1.85× | ||
| Q3 25 | 1.78× | 2.97× | ||
| Q2 25 | 1.62× | 2.49× | ||
| Q1 25 | 0.81× | 3.03× | ||
| Q4 24 | 2.59× | 1.84× | ||
| Q3 24 | 2.14× | 1.57× | ||
| Q2 24 | 2.52× | 2.87× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BSX
| Cardiovascular | $3.1B | 59% |
| Endoscopy | $673.0M | 13% |
| Urology | $633.0M | 12% |
| Other | $386.0M | 7% |
| Neuromodulation | $271.0M | 5% |
| LACA | $155.0M | 3% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
